A5053128035- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Chemotherapy-related skin toxicity
- Pancreatic and Hepatic Oncology Research
- Health Systems, Economic Evaluations, Quality of Life
- Advances in Oncology and Radiotherapy
- Economic and Financial Impacts of Cancer
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Glioma Diagnosis and Treatment
- Cancer Research and Treatments
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
University Hospital Limerick
2025
University of Limerick
2025
University of Glasgow
2009-2024
Hôpital Lyon Sud
2000-2023
Centre Hospitalier René-Dubos
2000-2023
Sorbonne Université
2000-2023
Hôpital Saint-Antoine
2000-2023
Memorial Sloan Kettering Cancer Center
2006-2023
Marqués de Valdecilla University Hospital
2008-2023
CancerCare Manitoba
2007-2023
PURPOSE: In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to standard North Central Cancer Treatment Group/Mayo Clinic 5-day 5FU/LV regimen. This phase III investigated effect combining oxaliplatin with LV5FU2, progression-free survival as primary end point. PATIENTS AND METHODS: Four hundred twenty previously untreated patients measurable disease were...
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC).
Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine an established alternative to as first-line metastatic colorectal We evaluated in setting.
To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at tumor site, that intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer.We prospectively randomized 602 patients 1,250 mg/m(2) twice daily days 1 14 every 3 weeks, or 4-weekly Mayo Clinic regimen...
Purpose To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC). Patients Methods The initial design of this trial was a randomized, two-arm, noninferiority, phase III comparison XELOX versus FOLFOX-4. After patient accrual had begun, the amended 2003 after bevacizumab data became available. resulting 2 × factorial randomly assigned patients FOLFOX-4, then also receive...
Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC). Oxaliplatin shows synergy with fluorouracil (FU), little toxicity overlap. The XELOX regimen (capecitabine plus oxaliplatin), established in a previous dose-finding study, should improve on infused oxaliplatin FU and leucovorin (FOLFOX) regimens. present studies further characterize safety of the regimen.The antitumor activity was investigated colon xenograft model. Patients MCRC...
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC).
PURPOSE: To evaluate in patients with advanced colorectal cancer (CRC) three treatment regimens of oral capecitabine order to select the most appropriate regimen for testing phase III. PATIENTS AND METHODS: Three schedules were evaluated a randomized II design: arm A, 1,331 mg/m 2 /d bid continuously; B, 2,510 intermittently (2 weeks on/1 week off); and C, 1,657 plus leucovorin 60 mg/d off). RESULTS: One hundred nine randomized; 39 assessable efficacy 34 35 C. Patient characteristics...
We conducted a retrospective analysis of safety data from randomized, single-agent fluoropyrimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and capecitabine) to test the hypothesis that there are regional differences in tolerability.Treatment-related three phase III studies were analyzed by multivariate analysis: two comparing capecitabine with bolus FU/LV metastatic colorectal cancer (MCRC) one plus oxaliplatin (XELOX) as adjuvant treatment for colon cancer. The United States...
Preclinical studies have suggested accelerated tumor growth, local invasion, and distant metastasis after withdrawal of treatment with some antiangiogenic agents. To investigate whether discontinuation bevacizumab is associated disease progression or increased mortality, we retrospectively analyzed five randomized, placebo-controlled phase III in 4,205 patients breast, colorectal, renal, pancreatic cancer.Time from to progressive death was discontinuing bevacizumab/placebo as a result...
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether would be non-inferior to the usual treatment.The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk II and III cancer underwent central randomisation minimisation centre, choice regimen, sex, disease site, N stage, T starting dose capecitabine. were assigned...
Pre-clinical data indicate enhanced anti-tumour activity when combining recombinant human interleukin-21 (rIL-21), a class 1 cytokine, with cetuximab, monoclonal antibody, targeting the epidermal growth factor receptor. This phase trial assessed safety and tolerability of escalating doses rIL-21 in combination cetuximab chemo-naïve patients stage IV colorectal cancer. Sequential cohorts PS 0–1, asymptomatic patients, were treated weekly 250 mg m−2 intravenously (i.v.) plus i.v. following an...